Neurocrine Biosciences Inc NBIX
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. 10-K, Item 1
- Headquarters
- San Diego, CA
- CEO
- Kyle Gano
- Next results
- around Feb 10, 2027
Where each dollar of revenue went, FY2025
Revenue of $2.9B through the costs to a net profit of $478.6M · income statement of the 10-K
NBIX among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
31 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 11, 2026 against Feb 10, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Receivables growing faster than revenueReceivables +43.4% ($479.1M to $686.8M) vs revenue +21.4% ($2.4B to $2.9B), +21.9 pts apart
-
Cash from operations $782.7M vs net income $478.6M (FY ending Dec 31, 2025)
9 more checks with nothing to note
-
Inventory +20.2% ($57.4M to $69.0M) vs revenue +21.4% ($2.4B to $2.9B), -1.2 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Reserves for Medicaid rebates related to product sales
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
31 paragraphs in Risk Factors that were not in the 10-K filed Feb 10, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
Legislators, policymakers, and payors may continue to propose and implement cost-containing measures to keep healthcare costs down. For example, in April 2025, the President issued an executive order that, among other things, directed specified agency heads to develop a Center for Medicare and Medicaid Innovation (CMMI) model that…
-
Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate. Because we believe our continued growth and success depend in part on our ability to identify (by internal development, in-license or acquisition), develop and ultimately commercialize a steady number of…
-
Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
Further, changes in federal policy could affect the geopolitical landscape and could give rise to circumstances that negatively affect our business. The third parties that manufacture our products have manufacturing facilities located in Europe. The U.S. has implemented, and has proposed to further implement, tariffs that may increase…
-
Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified, or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. Federal laws such as the One Big Beautiful Bill Act (OBBBA), enacted in 2025, the…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.5B | $1.9B | $2.4B | $2.9B |
| Net income | $154.5M | $249.7M | $341.3M | $478.6M |
| Operating cash flow | $339.4M | $389.9M | $595.4M | $782.7M |
| Free cash flow | $322.9M | $361.6M | $557.2M | $748.7M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.9B ▲ 21.4% in FY2025$478.6M ▲ 40.2% in FY2025$748.7M ▲ 34.4% in FY2025
Recent filings
11 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 10, 2026SANJAY KESWANI (Former Affiliate) gave notice of a planned sale of 53,614 shares worth about $9.0M Form 144, approximate sale date Nov 10, 2026
-
Planned saleNov 2, 2026GEORGE MORROW (Director) gave notice of a planned sale of 14,700 shares worth about $2.1M Form 144, approximate sale date Nov 2, 2026, under a 10b5-1 plan adopted May 26, 2026
-
Planned saleNov 2, 2026Sanjay Keswani (Chief Medical Officer (through Sep. 25, 2026)) adopted a 10b5-1 trading plan reported in the 10-Q, up to 11,200 shares, runs to Jan 30, 2027
-
Planned saleNov 2, 2026David Boyer (Chief Corporate Affairs Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 4,512 shares, runs to May 18, 2028
-
Planned saleNov 2, 2026Gary Lyons (Director) adopted a 10b5-1 trading plan reported in the 10-Q, up to 15,000 shares, runs to May 22, 2027
About the company
Neurocrine Biosciences Inc, San Diego, CA · from the 10-K filed Feb 11, 2026
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc.
- Headquarters
- San Diego, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 2, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 11, 2026 (open at SEC), compared with the 10-K filed Feb 10, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NBIX/export.csv") into a cell.